147 related articles for article (PubMed ID: 37160416)
21. The clinicopathological significance of miR-149 and PARP-2 in hepatocellular carcinoma and their roles in chemo/radiotherapy.
Lin L; Zhang YD; Chen ZY; Chen Y; Ren CP
Tumour Biol; 2016 Sep; 37(9):12339-12346. PubMed ID: 27300349
[TBL] [Abstract][Full Text] [Related]
22. Patient-reported outcomes with atezolizumab plus bevacizumab versus sorafenib in patients with unresectable hepatocellular carcinoma (IMbrave150): an open-label, randomised, phase 3 trial.
Galle PR; Finn RS; Qin S; Ikeda M; Zhu AX; Kim TY; Kudo M; Breder V; Merle P; Kaseb A; Li D; Mulla S; Verret W; Xu DZ; Hernandez S; Ding B; Liu J; Huang C; Lim HY; Cheng AL; Ducreux M
Lancet Oncol; 2021 Jul; 22(7):991-1001. PubMed ID: 34051880
[TBL] [Abstract][Full Text] [Related]
23. Atezolizumab with or without bevacizumab in unresectable hepatocellular carcinoma (GO30140): an open-label, multicentre, phase 1b study.
Lee MS; Ryoo BY; Hsu CH; Numata K; Stein S; Verret W; Hack SP; Spahn J; Liu B; Abdullah H; Wang Y; He AR; Lee KH;
Lancet Oncol; 2020 Jun; 21(6):808-820. PubMed ID: 32502443
[TBL] [Abstract][Full Text] [Related]
24. MicroRNA-197 Promotes Metastasis of Hepatocellular Carcinoma by Activating Wnt/β-Catenin Signaling.
Hu Z; Wang P; Lin J; Zheng X; Yang F; Zhang G; Chen D; Xie J; Gao Z; Peng L; Xie C
Cell Physiol Biochem; 2018; 51(1):470-486. PubMed ID: 30453289
[TBL] [Abstract][Full Text] [Related]
25. [A Case of Multiple Postoperative Recurrence of Hepatocellular Carcinoma Successfully Treated with Atezolizumab plus Bevacizumab].
Fujii J; Shinke G; Takeda Y; Ohmura Y; Katsura Y; Kinoshita M; Aoyama S; Kihara Y; Katsuyama S; Ikeshima R; Hiraki M; Sugimura K; Masuzawa T; Hata T; Murata K
Gan To Kagaku Ryoho; 2023 Jan; 50(1):96-98. PubMed ID: 36759998
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of Atezolizumab Plus Bevacizumab vs Sorafenib for Patients With Unresectable or Metastatic Hepatocellular Carcinoma.
Zhang X; Wang J; Shi J; Jia X; Dang S; Wang W
JAMA Netw Open; 2021 Apr; 4(4):e214846. PubMed ID: 33825837
[TBL] [Abstract][Full Text] [Related]
27. AXIN deficiency in human and mouse hepatocytes induces hepatocellular carcinoma in the absence of β-catenin activation.
Abitbol S; Dahmani R; Coulouarn C; Ragazzon B; Mlecnik B; Senni N; Savall M; Bossard P; Sohier P; Drouet V; Tournier E; Dumont F; Sanson R; Calderaro J; Zucman-Rossi J; Vasseur-Cognet M; Just PA; Terris B; Perret C; Gilgenkrantz H
J Hepatol; 2018 Jun; 68(6):1203-1213. PubMed ID: 29525529
[TBL] [Abstract][Full Text] [Related]
28. Atezolizumab plus bevacizumab for unresectable or metastatic hepatocellular carcinoma.
D'Alessio A; Cammarota A; Zanuso V; Pressiani T; Personeni N; Rimassa L
Expert Rev Anticancer Ther; 2021 Sep; 21(9):927-939. PubMed ID: 34167423
[No Abstract] [Full Text] [Related]
29. Evans' syndrome induced by atezolizumab plus bevacizumab combination therapy in advanced hepatocellular carcinoma.
Fukushima M; Tajima K; Sasaki R; Nakao Y; Takahashi K; Ozawa E; Miuma S; Kato T; Miyaaki H; Nakao K
Clin J Gastroenterol; 2023 Jun; 16(3):402-406. PubMed ID: 36746879
[TBL] [Abstract][Full Text] [Related]
30. Effects of Atezolizumab and Bevacizumab on Adrenal Gland Metastasis of Hepatocellular Carcinoma: A Case Report and Review of Literature.
Ishikawa N; Kamimura K; Endo S; Ishii S; Ogawa K; Sakai N; Abe H; Ko M; Shibata O; Koseki Y; Yokoyama J; Sakamaki A; Terai S
Intern Med; 2022 Nov; 61(21):3233-3237. PubMed ID: 35431306
[TBL] [Abstract][Full Text] [Related]
31. BAP1 mutations define a homogeneous subgroup of hepatocellular carcinoma with fibrolamellar-like features and activated PKA.
Hirsch TZ; Negulescu A; Gupta B; Caruso S; Noblet B; Couchy G; Bayard Q; Meunier L; Morcrette G; Scoazec JY; Blanc JF; Amaddeo G; Nault JC; Bioulac-Sage P; Ziol M; Beaufrère A; Paradis V; Calderaro J; Imbeaud S; Zucman-Rossi J
J Hepatol; 2020 May; 72(5):924-936. PubMed ID: 31862487
[TBL] [Abstract][Full Text] [Related]
32. Complete tumor necrosis confirmed by conversion hepatectomy after atezolizumab-bevacizumab treatment for advanced-stage hepatocellular carcinoma with lung metastasis.
Fukunaga A; Takata K; Itoh S; Yamauchi R; Tanaka T; Yokoyama K; Shakado S; Kohashi K; Yoshizumi T; Hirai F
Clin J Gastroenterol; 2023 Apr; 16(2):224-228. PubMed ID: 36495383
[TBL] [Abstract][Full Text] [Related]
33. Integrative analysis of aberrant Wnt signaling in hepatitis B virus-related hepatocellular carcinoma.
Ding SL; Yang ZW; Wang J; Zhang XL; Chen XM; Lu FM
World J Gastroenterol; 2015 May; 21(20):6317-28. PubMed ID: 26034368
[TBL] [Abstract][Full Text] [Related]
34. Mixed hepatocellular cholangiocarcinoma tumors: Cholangiolocellular carcinoma is a distinct molecular entity.
Moeini A; Sia D; Zhang Z; Camprecios G; Stueck A; Dong H; Montal R; Torrens L; Martinez-Quetglas I; Fiel MI; Hao K; Villanueva A; Thung SN; Schwartz ME; Llovet JM
J Hepatol; 2017 May; 66(5):952-961. PubMed ID: 28126467
[TBL] [Abstract][Full Text] [Related]
35. Atezolizumab and bevacizumab for hepatocellular carcinoma: mechanism, pharmacokinetics and future treatment strategies.
Liu X; Lu Y; Qin S
Future Oncol; 2021 Jun; 17(17):2243-2256. PubMed ID: 33663220
[TBL] [Abstract][Full Text] [Related]
36. Phase II Studies with Refametinib or Refametinib plus Sorafenib in Patients with
Lim HY; Merle P; Weiss KH; Yau T; Ross P; Mazzaferro V; Blanc JF; Ma YT; Yen CJ; Kocsis J; Choo SP; Sukeepaisarnjaroen W; Gérolami R; Dufour JF; Gane EJ; Ryoo BY; Peck-Radosavljevic M; Dao T; Yeo W; Lamlertthon W; Thongsawat S; Teufel M; Roth K; Reis D; Childs BH; Krissel H; Llovet JM
Clin Cancer Res; 2018 Oct; 24(19):4650-4661. PubMed ID: 29950351
[No Abstract] [Full Text] [Related]
37. Influence of polymorphisms in the Wnt/β-catenin pathway genes on hepatocellular carcinoma risk in a Chinese Han population.
Li QM; Zhang FQ; Li YF; Xian QJ; Zhang YQ; Li P
Medicine (Baltimore); 2017 Mar; 96(12):e6127. PubMed ID: 28328801
[TBL] [Abstract][Full Text] [Related]
38. Accumulation of Molecular Aberrations Distinctive to Hepatocellular Carcinoma Progression.
Midorikawa Y; Yamamoto S; Tatsuno K; Renard-Guillet C; Tsuji S; Hayashi A; Ueda H; Fukuda S; Fujita T; Katoh H; Ishikawa S; Covington KR; Creighton CJ; Sugitani M; Wheeler DA; Shibata T; Nagae G; Takayama T; Aburatani H
Cancer Res; 2020 Sep; 80(18):3810-3819. PubMed ID: 32641413
[TBL] [Abstract][Full Text] [Related]
39. Atezolizumab-bevacizumab plus Y-90 TARE for the treatment of hepatocellular carcinoma: preclinical rationale and ongoing clinical trials.
Di Federico A; Rizzo A; Carloni R; De Giglio A; Bruno R; Ricci D; Brandi G
Expert Opin Investig Drugs; 2022 Apr; 31(4):361-369. PubMed ID: 34798793
[TBL] [Abstract][Full Text] [Related]
40. Conversion Surgery After Atezolizumab Plus Bevacizumab for Primary and Peritoneal Metastasis After Hepatocellular Carcinoma Rupture.
Miyata T; Sugi K; Horino T; Ono A; Tagayasu Y; Nomoto D; Inoue M; Mizumoto T; Kubota T; Yanagida E; Murayama T; Miyanari N; Baba H
Anticancer Res; 2023 Feb; 43(2):943-947. PubMed ID: 36697062
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
